National Personal Injury Attorney Wendy Fleishman Comments On FDA Warning On Safety of Yaz Birth Control

Attorney Represents Women Across America in Yaz Injury Lawsuits Against Bayer

NEW YORK--(BUSINESS WIRE)-- The U.S. Food and Drug Administration issued a statement today that the FDA remains concerned, but has not yet reached a conclusion, about the potential increased risk of blood clots from Drospirenone-containing birth control pills such as YAZ, YASMIN, BEYAZ, and OCELLA, among others.

Preliminary results from an FDA-sponsored study of 800,000 women taking birth control pills shows that there is a 1.5 increased risk among Drospirenone-containing pill users.

To address these concerns, the FDA has scheduled an important meeting for December 8, 2011. The FDA will hear testimony concerning these studies and the safety of these medications. The meeting is open to the public.

Commenting on the FDA warning, Wendy Fleishman, a prominent personal injury attorney with the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, stated, “Too many active and healthy women have suddenly died from, or suffered severe, life-threatening blood clots allegedly caused by taking Drospirenone-containing birth control pills, like YAZ. We are wholly supportive of birth control choices for young women, but women need to be accurately informed of the potential risks when they take a birth control pill. We hope that the FDA's review will cause Bayer to take the responsible course of action and fully disclose the dangers this drug poses.”

YAZ Birth Control Injury Law - Legal Resources for Patients

If you or a family member have suffered a serious injury or a loved one died after being prescribed YAZ or YASMIN, please visit http://www.yazbirthcontrolinjurylaw.com/ to learn more about your legal rights, watch a short video on the risks posed by YAZ and YASMIN, and submit your complaint.

Experienced personal injury attorneys at Lieff Cabraser will promptly review each case submitted without charge or obligation.

Trademark Notice

Yaz and Yasmin are registered trademarks of Bayer Schering Pharma Aktiengesellschaft and used for informational and product identification purposes only.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, is a sixty-plus attorney law firm founded in 1972 with offices in San Francisco, New York and Nashville. Described by The American Lawyer as “one of the nation’s premier plaintiffs’ firms,” Lieff Cabraser enjoys a national reputation for professional integrity and the successful prosecution of our clients’ claims.

In the 2010 edition of its annual list of the top plaintiffs’ law firms, The National Law Journal again selected Lieff Cabraser. Lieff Cabraser is one of only two plaintiffs’ law firms in the United States to receive this honor for the last eight years.

Learn more about our firm at www.lieffcabraser.com.



CONTACT:

Lieff Cabraser Heimann & Bernstein, LLP
Wendy R. Fleishman, 212-355-9500

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Women  Health  Collegiate  Pharmaceutical  Professional Services  Legal  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.